|
KMID : 0980120210190020021
|
|
Annals of Phlebology
2021 Volume.19 No. 2 p.21 ~ p.26
|
|
|
Venoactive Drugs, Summary of the Clinical Trials and Guidelines
|
|
Yun Sang-Chul
|
|
|
Abstract
|
|
|
|
The European Venous Forum guidelines recommend that venoactive drugs could be used as the primary treatment for symptoms and edema in all stages of chronic venous disease. In more advanced disease stages, venoactive drugs can be used in conjunction with surgery, sclerotherapy, thermal ablation, or compression therapy, and can improve the effectiveness of compression. It is usually not recommended to combine multiple venoactive drugs in the same prescription. Most venoactive drugs have common effects on swelling, pain, cramping, and weight. However, the clinical guidelines and the Cochrane review show that the effect is different for each drugs. Micronized purified flavonoid fractions might be more effective in venous ulcers, redness of the legs, and skin changes. Calcium dobesilate for restless legs syndrome, rutoside series for itching or abnormal sensations, and ruscus extract for fatigue are reportedly helpful in selecting appropriate venoactive drugs according to each symptom that patients complain of. In particular, the use of micronized purified flavonoid fraction seems to be possible for therapeutic purposes in patients with C0 and C1 who exhibit temporary venous reflux, and patients with venous ulcers and post thrombotic syndrome. Therefore, it is necessary to use appropriate venoactive drugs according to the patient’s symptoms and the severity of the disease.
|
|
|
KEYWORD
|
|
|
Varicose vein, Chronic venous insufficiency, Venoactive drugs, Clinical practice guidelines, Cochrane review
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|